Background: Chronic hepatitis caused by infection with hepatitis C virus C (chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide. For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection. IFNα binds to its cognate cell surface receptor (IFNAR) and activates the Jak-STAT pathway, thereby regulating the expression of hundreds of genes. Collectively, IFNα induced effector proteins establish an antiviral state in the cell. IFNα signaling is regulated by inducible inhibitors of the Jak-STAT pathway such as SOCS1, SOCS3 and USP18. These negative regulators of IFNα signaling limit the therapeutic efficacy recombinant IFNα. Monotherapy with IFNα was the standard of care until 1998 and achieved a sustained virological response in 20-25% of patients. Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs, most notable ribavirin. However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment. Conclusions: A new generation of HCV-specific antiviral drugs will probably further improve response rates and might replace IFNs in CHC treatment in the next few years. Without CHC, recombinant pegIFNα will lose its most important clinical application. However, recombinant pegIFNα might still be used in the treatment of chronic hepatitis B and chronic hepatitis D. Recombinant IFNs will hopefully be maintained in the ‘therapeutic armamentarium’, because their broad antiviral effects might become invaluable for the treatment of emerging viral infections in the future.